Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking and Finance Review

Global Banking and Finance Review - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Headlines > Novo Nordisk buys Akero Therapeutics in the US
    Headlines

    Novo Nordisk buys Akero Therapeutics in the US

    Published by Global Banking and Finance Review

    Posted on October 9, 2025

    1 min read

    Last updated: January 21, 2026

    Novo Nordisk buys Akero Therapeutics in the US - Headlines news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:innovationacquisitionhealthcareinvestment

    Quick Summary

    Novo Nordisk has acquired Akero Therapeutics, a US-based company, to enhance its offerings in treating metabolic diseases with high unmet needs.

    Novo Nordisk buys Akero Therapeutics in the US

    Overview of the Acquisition

    STOCKHOLM (Reuters) -Danish drugmaker Novo Nordisk said on Thursday it had agreed to buy United States based Akero Therapeutics, a clinical-stage company developing innovative treatments for patients with serious metabolic diseases marked by a high unmet medical need.

    Details of the Deal

    (Reporting by Anna Ringstrom, editing by Essi Lehto)

    Key Takeaways

    • •Novo Nordisk has acquired Akero Therapeutics.
    • •Akero specializes in treatments for metabolic diseases.
    • •The acquisition addresses high unmet medical needs.
    • •This move strengthens Novo Nordisk's portfolio.
    • •The deal was reported by Reuters.

    Frequently Asked Questions about Novo Nordisk buys Akero Therapeutics in the US

    1What is an acquisition?

    An acquisition is a corporate action in which one company purchases most or all of another company's shares to gain control of that company.

    2What is a clinical-stage company?

    A clinical-stage company is a business that is in the process of developing and testing its products or therapies in clinical trials before they can be marketed.

    More from Headlines

    Explore more articles in the Headlines category

    Image for Oil falls on possible US-Iran de-escalation, firm dollar
    Oil falls on possible US-Iran de-escalation, firm dollar
    Image for Son of Norway's crown princess stands trial for rape and domestic violence
    Son of Norway's crown princess stands trial for rape and domestic violence
    Image for Activist shareholder ACCR, pension funds urge BP to show shift to oil and gas will deliver value
    Activist shareholder ACCR, pension funds urge BP to show shift to oil and gas will deliver value
    Image for Google Cloud, Liberty Global strike five-year AI partnership
    Google Cloud, Liberty Global strike five-year AI partnership
    Image for Ukraine's capital of Kyiv, other cities under Russian attack, officials say
    Ukraine's capital of Kyiv, other cities under Russian attack, officials say
    Image for EU proposals set to limit EV sales from 2035, says campaign group
    EU proposals set to limit EV sales from 2035, says campaign group
    Image for Trading Day: Solid data over hard assets
    Trading Day: Solid data over hard assets
    Image for Queen's University Belfast cuts ties with US politician Mitchell over Epstein files
    Queen's University Belfast cuts ties with US politician Mitchell over Epstein files
    Image for UK police review reports of alleged misconduct by Mandelson after Epstein files release
    UK police review reports of alleged misconduct by Mandelson after Epstein files release
    Image for Russia says foreign forces in Ukraine would be 'legitimate targets'
    Russia says foreign forces in Ukraine would be 'legitimate targets'
    Image for Swiss National Bank Chairman says current situation not easy for policy
    Swiss National Bank Chairman says current situation not easy for policy
    Image for Recycling body opposes EU scrap aluminium export curbs
    Recycling body opposes EU scrap aluminium export curbs
    View All Headlines Posts
    Previous Headlines PostNovo to buy Akero for up to $5.2 billion in new CEO's revival push
    Next Headlines PostGaza aid plan will fail without full access for humanitarian groups, says Norwegian Refugee Council